No DFS Benefit With Adjuvant Durvalumab in Early NSCLC

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in the CCTG BR.31 trial underscores the need to identify biomarkers.
Medscape Medical News

source https://www.medscape.com/viewarticle/no-dfs-benefit-adjuvant-durvalumab-early-nsclc-2024a1000gpx?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost